Pacific Bio (PACB) Reports In-Line Q4 EPS, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts PACB Hot Sheet
Join SI Premium – FREE
Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.20), in-line with the analyst estimate of ($0.20). Revenue for the quarter came in at $39.2 million versus the consensus estimate of $40.61 million.
For earnings history and earnings-related data on Pacific Bio (PACB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Texas Capital Securities Downgrades Full House Resorts (FLL) to Hold
- Evercore ISI on Duolingo Inc. (DUOL), 'remains one of our top SMiDcap picks'
- Eastman Chemical (EMN) PT Lowered to $72 at Goldman Sachs
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
